Herbert Kaltner

This study shows that Galectin-1 reduces atherosclerotic plaque formation by reprogramming macrophages and modulating T cell immunity through both glycan-dependent and -independent mechanisms.

This study identifies SOX2 and SOX9 as regulators of LGALS3 promoter activity in SW1353 cells, showing dose-dependent repression and SOX9 binding.

This study investigates Galectin-1's specificity for GM1 over GD1a in lipid membranes and finds no evidence of cross-linking by homodimers.